title: Gateways to clinical trials.
abstract: 1E10, 101M; AAV-ASPA, agomelatine, aliskiren fumarate, alvimopan hydrate, ambrisentan, apaziquone, axitinib; Becatecarin, belagenpumatucel-L, BMS-201038; Cannabidiol, Cannabis sativa L. extract, capromorelin, CBP-501, cediranib, cetuximab, CHR-2797; Dapoxetine hydrochloride, degarelix acetate, desvenlafaxine succinate, dimethyl fumarate, dronedarone hydrochloride; Ecogramostim, eprodisate sodium; Falciparum merozoite protein-1/AS02A, fospropofol disodium; Gefitinib, glucarpidase, GTI-2040; Hepatitis C vaccine, HMR-4902, human proinsulin C-peptide, hyaluronic acid; Ipilimumab, ixabepilone; Lapatinib, lenalidomide, lestaurtinib, liposome encapsulated doxorubicin; Manidipine hydrochloride/delapril hydrochloride, metreleptin, MG-98, MGCD-0103, morphine glucuronide; Nebicapone; O6-benzylguanine, ofatumumab, olmesartan medoxomil/hydrochlorothiazide; PAN-811, pemetrexed disodium, perifosine, pertuzumab, Peru-15, pexelizumab, pirfenidone, pralatrexate, prasugrel; Quercetin; Rivaroxaban; Semaxanib, St. John's Wort extract; Ticagrelor, tomopenem, triplatin tetranitrate; Ulipristal acetate; Vandetanib, vatalanib succinate, vildagliptin; XK-469; ZT-1.
authors.affiliation: Prous Science, Barcelona, Spain. mbayes@prous.com
authors.forename: Miriam
authors.initials: M
authors.lastname: Bayes
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
authors.forename: J R
authors.initials: JR
authors.lastname: Prous
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans